Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. First-Line Pazopanib Treatment in Metastatic RCC: Real-World Data From a Single Chinese Center
  2. Predictive Value of PD-L1 in Patients With Metastatic RCC Treated With Immune Checkpoint Inhibitors
  3. Prognostic Significance of Sarcomatoid Differentiation in Patients With mRCC
  4. Probiotic Supplementation Modulates Gut Microbiome and Clinical Outcome From Targeted Therapy in mRCC
  5. Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma
  6. Quantification of Body Composition in RCC Patients: Comparing CT and MRI Measurements
  7. COVID-19 and Financial Toxicity in Patients With RCC
  8. Pembrolizumab Plus Axitinib vs Sunitinib Monotherapy as First-Line Treatment of Advanced Renal Cell Carcinoma
  9. Prognostic Molecular Signatures for Metastatic Potential in Clinically Low-Risk Stage I/II ccRCC
  10. Immune-Related Adverse Events in Advanced Kidney Cancer

Elsewhere

Recently Updated